dc.contributor.author | Lalondrelle, S | |
dc.contributor.author | Lee, J | |
dc.contributor.author | Cutts, RJ | |
dc.contributor.author | Garcia Murillas, I | |
dc.contributor.author | Matthews, N | |
dc.contributor.author | Turner, N | |
dc.contributor.author | Harrington, K | |
dc.contributor.author | Vroobel, K | |
dc.contributor.author | Moretti, E | |
dc.contributor.author | Bhide, SA | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2023-05-11T14:37:06Z | |
dc.date.available | 2023-05-11T14:37:06Z | |
dc.date.issued | 2023-02-22 | |
dc.identifier | ARTN 1387 | |
dc.identifier | cancers15051387 | |
dc.identifier.citation | Cancers, 2023, 15 (5), pp. 1387 - | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5783 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.doi | 10.3390/cancers15051387 | |
dc.description.abstract | BACKGROUND: The majority of locally advanced cervical cancers (LaCC) are causally related to HPV. We sought to investigate the utility of an ultra-sensitive HPV-DNA next generation sequencing (NGS) assay-panHPV-detect-in LaCC treated with chemoradiotherapy, as a marker of treatment response and persistent disease. METHOD: Serial blood samples were collected from 22 patients with LaCC before, during and after chemoradiation. The presence of circulating HPV-DNA was correlated with clinical and radiological outcomes. RESULTS: The panHPV-detect test demonstrated a sensitivity and specificity of 88% (95% CI-70-99%) and 100% (95% CI-30-100%), respectively, and correctly identified the HPV-subtype (16, 18, 45, 58). After a median follow up of 16 months, and three relapses all had detectable cHPV-DNA at 3 months post-CRT despite complete response on imaging. Another four patients with radiological partial or equivocal response and undetectable cHPV-DNA at the 3-month time point did not go on to develop relapse. All patients with radiological CR and undetectable cHPV-DNA at 3-months remained disease free. CONCLUSIONS: These results demonstrate that the panHPV-detect test shows high sensitivity and specificity for detecting cHPV-DNA in plasma. The test has potential applications in assessment of the response to CRT and in monitoring for relapse, and these initial findings warrant validation in a larger cohort. | |
dc.format | Electronic | |
dc.format.extent | 1387 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | MDPI | |
dc.relation.ispartof | Cancers | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | cervical cancer | |
dc.subject | circulating DNA | |
dc.subject | next generation sequencing | |
dc.subject | plasma HPV DNA | |
dc.subject | response prediction | |
dc.title | Predicting Response to Radical Chemoradiotherapy with Circulating HPV DNA (cHPV-DNA) in Locally Advanced Uterine Cervix Cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-02-21 | |
dc.date.updated | 2023-05-11T13:08:36Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.3390/cancers15051387 | |
rioxxterms.licenseref.startdate | 2023-02-22 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36900180 | |
pubs.issue | 5 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Gynaecological Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Gynaecological Cancer/Gynaecological Cancer (hon.) | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3390/cancers15051387 | |
pubs.volume | 15 | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Cutts, Rosalind | |
dc.contributor.icrauthor | Turner, Nicholas | |
dc.contributor.icrauthor | Harrington, Kevin | |
icr.provenance | Deposited by Mr Arek Surman on 2023-05-11. Deposit type is initial. No. of files: 1. Files: Predicting Response to Radical Chemoradiotherapy with Circulating HPV DNA (cHPV-DNA) in Locally Advanced Uterine Cervix Canc.pdf | |